Antimicrobial and antibiofilm activities of Cu(II) Schiff base complexes against methicillin-susceptible and resistant Staphylococcus aureus

Copper(II) carboxylate complexes inhibit Staphylococcus aureus biofilm formation by targeting extracellular proteins

Three copper(II) complexes of diphenyl acetic acid (DPAA) pyridine (py), 2,2΄-dipyridylamine (dpa), and 4,7-diphenyl, 1,10-phenanthroline (di-phen), [Cu₂(DPAA)₄(py)2] (Cu-1), [Cu(DPAA)₂(dpa)] (Cu-2), and [Cu₂(DPAA)₄(di-phen)₂] (Cu-3) were synthesized and characterized. Their antibacterial activities were evalvated. The minimum inhibitory concentrations (MIC) of these complexes against six tested microbial strains ranged from 1 to 128 μg/mL, and that of vancomycin antibiotic ranged from 0.5 to 2 μg/mL. The bactericidal effects of Cu-1, Cu-2 and Cu-3 and vancomycin against Staphylococcus aureus (S. aureus) were determined by colony count assay. Cu-1, Cu-2, and vancomycin showed relatively weaker antibiofilm formation activities; however, Cu-3 showed enhanced activity against S. aureus proliferation and biofilm formation as confirmed by microscopic analysis. In antibiofilm assays, Cu-1, Cu-2 and Cu-3 demonstrated high inhibition ability (23-75 %), of mature biofilm formation at concentrations of 5 to 15 μg/mL, and vancomycin at 15 μg/mL inhibited only 47 %. Cu-3 also effectively killed S. aureus within biofilms at doses up to 2 × MIC μg/mL. Further analysis of extracellular proteins (ECPs) expression revealed, that Cu-3 had significant potential in suppressing ECPs production. Molecular docking (MD) studies with biofilm associated protein (Bap) and SARS-CoV-2 receptors showed high interactions by several bonding types, where Cu-2 found as potent antiviral agent. Collectively, these findings highlighted the copper complexes potential in antibacterial applications, with Cu-3 emerging as a potent candidate for S. aureus biofilm inhibition.

Evaluation of the therapeutic potential of a Schiff Base Compound: Pharmacokinetic profiling, molecular docking for Enoyl-Acyl carrier protein reductase (InhA), antimicrobial, and anticancer properties

This study investigates the therapeutic potential of a Schiff base compound (phenolphthalein derivate appended 2-furoic hydrazide) using in silico drug similarity predictions, molecular docking, and in vitro antimicrobial and cytotoxicity assays. Despite low solubility (LogS -5.564) and gastrointestinal absorption challenges, the compound demonstrates moderate lipophilicity (LogP 3.459) and strong binding affinity to mycobacterial targets, including enoyl-acyl carrier protein reductase (InhA) in Mycobacterium tuberculosis (-9.11 kcal/mol), suggesting antimicrobial potential. In vitro antimicrobial assays show significant activity against Gram-positive (Bacillus cereus, Bacillus licheniformis) with a minimum inhibitory concentration (MIC) of 0.1 mM. The compound is bactericidal against Gram-positive bacteria and bacteriostatic against Gram-negative bacteria. Cytotoxicity tests on liver cancer (Mahlavu), normal liver (THLE2), and breast cancer (MCF7) cell lines reveal dose-dependent decreases in cell viability, with IC50 values of 8.77 ± 0.39 μM (Mahlavu), 10.78 ± 0.43 μM (THLE2), and 19.25 ± 2.97 μM (MCF7), indicating selective anticancer activity, particularly in liver cells. While the compound shows promising antimicrobial and anticancer effects, concerns about bioavailability, drug-drug interactions, and toxicity require further optimization. Enhancing its pharmacokinetic properties and investigating metal complexes could improve its therapeutic potential for clinical use.

A multi-dimensional validation strategy of pharmacological effects of Radix Isatidis Mixtures against the co-infection of Mycoplasma gallisepticum and Escherichia coli in poultry

Natural drugs possess exceptional pharmacological properties, yet their development is often hindered by a lack of clarity regarding the mechanisms of their pharmacological actions. Building on our previous research, we employed a co-infection model with Mycoplasma gallisepticum (MG) and Escherichia coli (E. coli) to investigate the pharmacological action of Radix Isatidis Mixtures (RIM). To further demonstrate the various mechanisms underlying the pharmacological effects of RIM, we conducted a validation study focusing on gene expression, protein interactions, metabolic pathways, and molecular docking. Through a multi-omics joint analysis network, we identified key targets and metabolites associated with co-infection and conducted targeted verification experiments with RIM aqueous extracts. The experimental results indicated that, compared to the co-infection group, the RIM treatment group significantly modulated the expression of select genes and proteins, particularly MMP2 and TLR4, with a high level of statistical significance (p < 0.01). At the metabolic level, the treatment group exhibited significantly reduced expression levels of Dopamine and γ-Aminobutyric acid. Notably, the molecular docking results highlighted compounds with the most favorable binding affinities: Salvianolic acid A (-10.1 kcal/mol), Licorice (-9.3 kcal/mol), and Isoglycyrrhiza (-8.7 kcal/mol). In conclusion, our multi-level experiments demonstrated that RIM possesses the characteristics of multi-pathway and multi-target treatment for co-infection.

Highly Fluorescent π-Conjugated Azomethines and Divalent Metal Complexes as Antibacterial and Antibiofilm Nominees

π-Conjugated azomethine ligands differing in the naphthalene or phenylmethane-centered core structure and their divalent cobalt, nickel, copper, and zinc metal complexes were prepared and well-characterized by spectral analyses in solid state. Magnetic natures of the complexes were determined by magnetic susceptibility measurements in solid-state. Their remarkable photophysical characteristics were recorded by Uv-vis and Fluorescence spectroscopic techniques. At their excitation wavelenght of 265 nm, all molecules exhibited triple fluorescence emission bands with promising intensities above 673 nm in near infra-red region. Antibacterial and antibiofilm activities of the π-conjugated azomethines are promising for potential applications in medical and healthcare settings. Hence, the antibacterial/antibiofilm activity of the π-conjugated azomethine ligands and their metal complexes against some clinically important bacteria namely Staphylococcus aureus (MSSA), Methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus epidermidis, Escherichia coli, Pseudomonas aeruginosa and Proteus mirabilis was investigated, and the obtained results have shown that the ligands and complexes had a remarkable antibacterial effect, especially on Proteus mirabilis. Metal complexes have been found to have a significant inhibitory effect on biofilm formation by MRSA, MSSA, and P. mirabilis compared to ligands. The copper (II) complex of ligand-2 showed the highest inhibition percentage, significantly reducing biofilm formation for MRSA and MSSA. Furthermore, cobalt (II) complexes of the ligands selectively inhibited the growth of the opportunistic pathogen P. mirabilis biofilms, indicating that metal complexes might be a good choice for future antibiofilm studies.

1,2,3-Triazol-5-ylidene- vs. 1,2,3-triazole-based tricarbonylrhenium(I) complexes: influence of a mesoionic carbene ligand on the electronic and biological properties

The tricarbonylrhenium complexes that incorporate a mesoionic carbene ligand represent an emerging and promising class of molecules, the solid-state optical properties of which have rarely been investigated. The aim of this comprehensive study is to compare three of these complexes with their 1,2,3-triazole-based analogues. The Hirshfeld surface analysis of the crystallographic data revealed that the triazolylidene derivatives are more prone to π-π interactions than their 1,2,3-triazole-based counterparts. The FT-IR and electrochemical data indicated a stronger electron donor effect from the organic ligand to the rhenium atom for triazolylidene derivatives, which was confirmed by DFT calculations. All compounds were phosphorescent in solution, where the 1,2,3-triazole-based complexes showed unusually strong dependence on dissolved oxygen. All compounds also emitted in the solid state, some of them exhibited marked solid-state luminescence enhancement (SLE) effect. The 1,2,3-triazole based complex Re-Phe even displayed astounding photoluminescence efficiency with quantum yield up to 0.69, and proved to be an excellent candidate for applications linked to aggregation-induced emission (AIE). Interestingly, one triazolylidene-based complex (Re-T-BOP) showed attractive antibacterial activity. This study highlights the potential of these new molecules for applications in the fields of photoluminescent and therapeutic materials, and provides the first bases for the design of efficient molecules in these research areas.

Unique aminothiazolyl coumarins as potential DNA and membrane disruptors towards Enterococcus faecalis

Aminothiazolyl coumarins as potentially new antimicrobial agents were designed and synthesized in an effort to overcome drug resistance. Biological activity assay revealed that some target compounds exhibited significantly inhibitory efficiencies toward bacteria and fungi including drug-resistant pathogens. Especially, aminothiazolyl 7-propyl coumarin 8b and 4-dichlorobenzyl derivative 11b exhibited bactericidal potential (MBC/MIC = 2) toward clinically drug-resistant Enterococcus faecalis with low cytotoxicity to human lung adenocarcinoma A549 cells, rapidly bactericidal effects and no obvious bacterial resistance development against E. faecalis. The preliminary antibacterial action mechanism studies suggested that compound 11b was able to disturb E. faecalis membrane effectively, and interact with bacterial DNA isolated from resistant E. faecalis through noncovalent bonds to cleave DNA, thus inhibiting the growth of E. faecalis strain. Further molecular modeling indicated that compounds 8b and 11b could bind with SER-1084 and ASP-1083 residues of gyrase-DNA complex through hydrogen bonds and hydrophobic interactions. Moreover, compound 11b showed low hemolysis and in vivo toxicity. These findings of aminothiazolyl coumarins as unique structural scaffolds might hold a large promise for the treatments of drug-resistant bacterial infection.

Copper affects virulence and diverse phenotypes of uropathogenic Proteus mirabilis

BACKGROUND

Copper plays a role in urinary tract infection (UTI) and urinary copper content is increased during Proteus mirabilis UTI. We therefore investigated the effect of copper on uropathogenic P. mirabilis and the underlying mechanisms, focusing on the virulence associated aspects.

METHODS

Mouse colonization, swarming/swimming assays, measurement of cell length, flagellin level and urease activity, adhesion/invasion assay, biofilm formation, killing by macrophages, oxidative stress susceptibility, OMPs analysis, determination of MICs and persister cell formation, RT-PCR and transcriptional reporter assay were performed.

RESULTS

We found that copper-supplemented mice were more resistant to be colonized in the urinary tract, together with decreased swarming/swimming, ureases activity, expression of type VI secretion system and adhesion/invasion to urothelial cells and increased killing by macrophages of P. mirabilis at a sublethal copper level. However, bacterial biofilm formation and resistance to oxidative stress were enhanced under the same copper level. Of note, the presence of copper led to increased ciprofloxacin MIC and more persister cell formation against ampicillin. In addition, the presence of copper altered the outer membrane protein profile and triggered expression of RcsB response regulator. For the first time, we unveiled the pleiotropic effects of copper on uropathogenic P. mirabilis, especially for induction of bacterial two-component signaling system regulating fitness and virulence.

CONCLUSION

The finding of copper-mediated virulence and fitness reinforced the importance of copper for prevention and therapeutic interventions against P. mirabilis infections. As such, this study could facilitate the copper-based strategies against UTI by P. mirabilis.

Ruthenium(II) polypyridyl complexes as emerging photosensitisers for antibacterial photodynamic therapy

Photodynamic therapy (PDT) has recently emerged as a potential valuable alternative to treat microbial infections. In PDT, singlet oxygen is generated in the presence of photosensitisers and oxygen under light irradiation of a specific wavelength, causing cytotoxic damage to bacteria. This review highlights different generations of photosensitisers and the common characteristics of ideal photosensitisers. It also focuses on the emergence of ruthenium and more specifically on Ru(II) polypyridyl complexes as metal-based photosensitisers used in antimicrobial photodynamic therapy (aPDT). Their photochemical and photophysical properties as well as structures are discussed while relating them to their phototoxicity. The use of Ru(II) complexes with recent advancements such as nanoformulations, combinatory therapy and photothermal therapy to improve on previous shortcomings of the complexes are outlined. Future perspectives of these complexes used in two-photon PDT, photoacoustic imaging and sonotherapy are also discussed. This review covers the literature published from 2017 to 2023.

Copper-Based Antibiotic Strategies: Exploring Applications in the Hospital Setting and the Targeting of Cu Regulatory Pathways and Current Drug Design Trends

Classical antibacterial drugs were designed to target specific bacterial properties distinct from host human cells to maximize potency and selectivity. These designs were quite effective as they could be easily derivatized to bear next-generation drugs. However, the rapid mutation of bacteria and their associated acquired drug resistance have led to the rise of highly pathogenic superbug bacterial strains for which treatment with first line drugs is no match. More than ever, there is a dire need for antibacterial drug design that goes beyond conventional standards. Taking inspiration by the body's innate immune response to employ its own supply of labile copper ions in a toxic attack against pathogenic bacteria, which have a very low Cu tolerance, this review article examines the feasibility of Cu-centric strategies for antibacterial preventative and therapeutic applications. Promising results are shown for the use of Cu-containing materials in the hospital setting to minimize patient bacterial infections. Studies directed at disrupting bacterial Cu regulatory pathways elucidate new drug targets that can enable toxic increase of Cu levels and perturb bacterial dependence on iron. Likewise, Cu intracellular chelation/prochelation strategies effectively induce bacterial Cu toxicity. Cu-based small molecules and nanoparticles demonstrate the importance of the Cu ions in their mechanism and display potential synergism with classical drugs.